

Mitapivat Pediatric Clinical Trial Program



A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects with Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-Label Extension Period

Key Eligibility Criteria

- Aged 1 to <18 years with central laboratory confirmation of pyruvate kinase (PK) deficiency (presence of ≥2 mutant alleles in the PKLR gene, of which ≥1 is a missense mutation)
- 6 to 26 transfusion episodes in the 52-week period before providing informed consent
- Have complete records of transfusion history for the 52 weeks before informed consent

Primary Endpoint

To determine effect of mitapivat on:

Transfusion reduction response, defined as a ≥33% reduction in the total RBC transfusion volume from Week 9 through Week 32 normalized by weight and actual study drug duration compared with the historical transfusion volume standardized by weight and to 24 weeks

Secondary Endpoints

To assess the effect of mitapivat on:

- Hb concentration
- Safety
- Iron metabolism and overload
- Health-related quality of life
- Pharmacokinetics

Individualized Screening Fixed-dose period dose-titration period 2:1 Randomization 10-50 mg BID* Optimized mitapivat dose Open-label 1-5 mg BID extension period **Mitapivat** 10-50 mg BID³ Mock optimized placebo dose 4-20 mg BID Placebo 1-5 mg BID* 8 weeks 8 weeks 24 weeks

*Dose of mitapivat or matched placebo based on patient's age and weight. BID = twice daily.

FULLY ENROLLED AND ONGOING

